BioSpace News Archive

ALK: Registration of Capital Increase of DKK 92,076 AA Shares and DKK 920,760 B Shares By the Issue of New Shares Completed

This release does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, securities to any person in the United States, Australia, Canada or Japan.

December 11, 2017

·

1 min read

Galapagos to Enter NASDAQ Biotech Index

The company will be included in NASDAQ Biotech Index on NASDAQ, effective 18 December 2017.

December 11, 2017

·

1 min read

Drug Development

argenx to Provide Updates on Phase I/II Clinical Trials of ARGX-110 in Acute Myeloid Leukemia and Cutaneous T-Cell Lymphoma During American Society of Hematology Annual Meeting

The workshop will be held Monday, December 11th at 12:00 pm EST.

December 11, 2017

·

6 min read

Drug Development

argenx Reports Positive Topline Results From Phase II Proof-of-Concept Trial of ARGX-113 (Efgartigimod) in Generalized Myasthenia Gravis

Favorable tolerability profile consistent with Phase 1 data.

December 11, 2017

·

8 min read

Drug Development

Targovax Announces That First Combination Trials With ONCOS-102 Have Passed Their Initial, Planned, Independent Safety Reviews

These are the first studies to investigate ONCOS-102 in combination with other drugs.

December 11, 2017

·

4 min read

Drug Development

Agios Presents Updated Data from DRIVE PK Study Demonstrating AG-348 is Well-Tolerated and Results in Clinically Relevant, Rapid and Sustained Hemoglobin Increases in Patients with Pyruvate Kinase Deficiency

DRIVE PK is an ongoing global open-label, Phase 2, safety and efficacy trial evaluating AG-348 in 52 adult, transfusion-independent patients with PK deficiency.

December 11, 2017

·

8 min read

Drug Development

ZIOPHARM Announces Presentation of Data from T-Cell Therapy Programs at ASH Annual Meeting

ZIOPHARM is advancing its non-viral Sleeping Beauty (SB) platform towards point-of-care (P-O-C) for very rapid manufacturing of genetically modified CAR+ T cells.

December 11, 2017

·

8 min read

Drug Development

CEL-SCI Reaches Full Enrollment in Pivotal Phase III Head and Neck Cancer Study

The primary endpoint of the study, a 10% improvement in overall survival of the Multikine treatment regimen plus Standard of Care (SOC) vs. Standard of Care alone, will be determined after a total of 298 deaths have occurred in these two main comparator arms of the study and have been recorded in the study database.

December 11, 2017

·

4 min read

Drug Development

Primary Analysis Results From Novartis Pivotal JULIET Trial Show Kymriah(TM) (Tisagenlecleucel) Sustained Complete Responses at Six Months in Adults With R/R DLBCL, a Difficult-to-Treat Cancer

The median duration of response was not reached.

December 11, 2017

·

17 min read

Drug Development

Epizyme Presents New Biomarker Data on Tazemetostat at the American Society of Hematology Annual Meeting

These data from the company’s ongoing Phase 2 clinical trial in non-Hodgkin lymphoma (NHL) highlight exploratory response biomarkers and interim correlative data which may have the potential to further refine the clinical application of tazemetostat.

December 11, 2017

·

5 min read